PMID- 18264760
OWN - NLM
STAT- MEDLINE
DCOM- 20090213
LR  - 20141120
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 113
IP  - 1
DP  - 2009 Jan
TI  - Axillary lymph node status of operable breast cancers by combined steroid 
      receptor and HER-2 status: triple positive tumours are more likely lymph node 
      positive.
PG  - 181-7
LID - 10.1007/s10549-008-9914-7 [doi]
AB  - AIMS: To examine the frequency of axillary lymph node (ALN) invasion of operable 
      breast cancers by their combined oestrogen receptor (ER), progesterone receptor 
      (PR) and HER-2 status. METHODS: 2227 recently operated cases in one centre were 
      retrieved from the Multidisciplinary Breast Centre database and stratified 
      according to their combined immunohistochemical (IHC) expression of ER/PR/HER-2 
      status. An equivocal HER-2 status was further analysed by Fluorescence in situ 
      Hybridisation (FISH). The following 6 groups were considered: ER(-)PR(-)HER-2(-) 
      (NNN; triple negative), ER(-)PR(-)HER-2(+) (NNP), ER(+)PR(-)HER-2(-) (PNN), 
      ER(+)PR(-)HER-2(+) (PNP), ER(+)PR(+)HER-2(- )(PPN), ER(+)PR(+)HER-2(+) (PPP; 
      triple positive). For ALN, the following variables were tested in uni- and 
      multivariate models: age at diagnosis (years), tumour size (mm), tumour grade, 
      ER, PR, HER-2 and the combined steroid receptor and HER-2 status. Likelihood 
      ratio chi(2)-tests were used for univariate analysis and logistic regression for 
      multivariate analysis. RESULTS: Triple positive tumours had a higher likelihood 
      of being ALN positive than others (56.2% versus 35.7%; P<0.0001). Univariate 
      logistic regression also withheld age, size, grade and HER-2 as predictors of ALN 
      involvement. Final multivariate logistic regression revealed age, size, grade and 
      PPP versus non-PPP to be independent predictors of ALN involvement; the odds 
      ratio (OR) and 95% CI for PPP versus non-PPP tumours was 2.169 (1.490-3.156). 
      CONCLUSION: Our data provide insight into the natural history of triple positive 
      breast carcinomas. Such tumours are more likely ALN positive than those with 
      another steroid receptor and HER-2 status. How these findings correlate with 
      breast cancer prognosis remains to be investigated.
FAU - Van Calster, Ben
AU  - Van Calster B
AD  - Multidisciplinary Breast Centre, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium.
FAU - Vanden Bempt, Isabelle
AU  - Vanden Bempt I
FAU - Drijkoningen, Maria
AU  - Drijkoningen M
FAU - Pochet, Nathalie
AU  - Pochet N
FAU - Cheng, Jiqiu
AU  - Cheng J
FAU - Van Huffel, Sabine
AU  - Van Huffel S
FAU - Hendrickx, Wouter
AU  - Hendrickx W
FAU - Decock, Julie
AU  - Decock J
FAU - Huang, Huei-Jean
AU  - Huang HJ
FAU - Leunen, Karin
AU  - Leunen K
FAU - Amant, Frederic
AU  - Amant F
FAU - Berteloot, Patrick
AU  - Berteloot P
FAU - Paridaens, Robert
AU  - Paridaens R
FAU - Wildiers, Hans
AU  - Wildiers H
FAU - Van Limbergen, Erik
AU  - Van Limbergen E
FAU - Weltens, Caroline
AU  - Weltens C
FAU - Timmerman, Dirk
AU  - Timmerman D
FAU - Van Gorp, Toon
AU  - Van Gorp T
FAU - Smeets, Ann
AU  - Smeets A
FAU - Van den Bogaert, Walter
AU  - Van den Bogaert W
FAU - Vergote, Ignace
AU  - Vergote I
FAU - Christiaens, Marie-Rose
AU  - Christiaens MR
FAU - Neven, Patrick
AU  - Neven P
LA  - eng
PT  - Journal Article
DEP - 20080209
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Aged
MH  - Aged, 80 and over
MH  - Axilla
MH  - Breast Neoplasms/epidemiology/*genetics/pathology/*surgery
MH  - Female
MH  - Genes, erbB-2
MH  - Humans
MH  - Likelihood Functions
MH  - Lymph Nodes/*pathology
MH  - Lymphatic Metastasis/*pathology
MH  - Middle Aged
MH  - Odds Ratio
MH  - Receptor, ErbB-2/*genetics
MH  - Receptors, Estrogen/analysis
MH  - Receptors, Progesterone/analysis
EDAT- 2008/02/12 09:00
MHDA- 2009/02/14 09:00
CRDT- 2008/02/12 09:00
PHST- 2007/02/19 00:00 [received]
PHST- 2008/01/22 00:00 [accepted]
PHST- 2008/02/12 09:00 [pubmed]
PHST- 2009/02/14 09:00 [medline]
PHST- 2008/02/12 09:00 [entrez]
AID - 10.1007/s10549-008-9914-7 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2009 Jan;113(1):181-7. doi: 10.1007/s10549-008-9914-7. 
      Epub 2008 Feb 9.